Abstract 375P
Background
To determined survival and prognostic factors for non-nasopharyngeal head and neck squamous cell carcinoma (HNSCC) patients treated with surgery followed by concurrent chemoradiotherapy (CCRT) or definitive CCRT (dCCRT), aiming to identify optimal chemotherapy doses.
Methods
This retrospective cohort study reviewed 277 non-NPC HNSCC patients treated with platinum-based CCRT at Rajavithi Hospital between January 1st, 2016 and April 30th, 2021. Clinical features, staging, treatment, and outcomes were collected and analyzed.
Results
Overall, 277 patients were diagnosed as HNSCC; median age: 55.9 years; male: 81.2%; ECOG 0-1: 98.9%. The clinical stage was I-III, IVa, and IVb in 23.8%, 53.4%, and 22.8%, respectively. Cisplatin was used in 39.0%, while carboplatin was used in 61.0%. 53.4% underwent surgery followed by CCRT while 46.6% underwent definitive CCRT. Patients treated with adjuvant CCRT led to significantly longer overall survival (OS) and disease-free survival (DFS) than definitive CCRT (HR: 0.54, p<0.001 for OS; HR: 0.61, p<0.001 for DFS). Higher stage and the presence of pathological risk factors were poor prognostic factors for OS in the adjuvant CCRT group, while higher stage and oral cavity and hypopharynx were associated with poorer OS in the definitive CCRT group. Among the interquartile range of cumulative doses (CDs), the study also found a statistically significant difference in OS and DFS for the dCCRT group with carboplatin at the 2nd Quartile compared to the others (6.75-8.58 AUC) (HR 0.38, 95%CI; 0.17-0.86, p=0.02 and HR 0.41, 95%CI; 0.18-0.91, p=0.03, respectively). There was no significant difference in OS/DFS between patients who received CDs of cisplatin of either less or more than 200 mg/m2 or carboplatin in adjuvant CCRT in all population.
Conclusions
This study showed comparable survival outcomes to historical data. Surgery followed by adjuvant CCRT remains the recommended approach. The CDs of cisplatin or carboplatin did not significantly impact outcomes. A trend towards improved survival with CDs within a specific range requires confirmation in further prospective studies.
Clinical trial identification
6518.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract